Diagnosis, prevention, and management of delirium in the intensive cardiac care unit - 23/01/21

Riassunto |
Delirium is a frequent complication in patients admitted to intensive cardiac care units (ICCU) with potentially severe consequences including increased risks of mortality, cognitive impairment and dependence at discharge, and longer times on mechanical ventilation and hospital stay. Delirium has been widely documented and studied in general intensive care units and in patients after cardiac surgery, but it has barely been studied in acute nonsurgical cardiac patients. Moreover, delirium (especially in its hypoactive form) is commonly misdiagnosed. We propose a protocol for delirium prevention and management in ICCUs.
A daily comprehensive assessment to improve detection should be done using validated scales (ie, confusion assessment method). Preventive measures are particularly relevance and constitute the basis of treatment as well, acting on reversible risk factors, including environmental interventions, such as quiet time, sleep promotion, family support, communication, and adequate treatment of pain and dyspnea. Pharmacological prophylaxis is not indicated with the exception of patients at risk of withdrawal syndrome but should only be used in patients with confirmed delirium. Dexmedetomidine is the drug of choice in patients with severe agitation, and those weaning from invasive mechanical ventilation.
As the complexity of ICCUs increases, clinical scenarios posing challenges for the management of delirium become more frequent. Efforts should be done to improve the identification of patients at risk during admission in order to establish preventive interventions to avoid this complication. Patient-centered protocols will increase the awareness of the healthcare professionals for better prevention and earlier diagnosis and will positively impact on prognosis.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| Funding: No extramural funding was used to support this work. |
|
| Disclosures: Dr. Cortés-Beringola, Dr. Vicent, Dr. Martín-Asenjo, Dr. Puerto, Dr. Domínguez-Pérez, Dr. Maruri, Dr. Moreno, have nothing to disclose. Dr. Vidan has received financial support for attending scientific meetings and consulting fees from Novartis and speaking fees from Aula Fresenius. Dr. Arribas has received research funding from Daiichi Sankyo, Impulse Dynamics, Medtronic, Boston Scientific, Bayer, Bristol Meyers Squibb, Abbott, Novartis and research and educational payments to the Cardiology Department from Janssen Cylag, Biosensors and Edwards. Dr. Bueno receives research funding from the Instituto de Salud Carlos III, Spain (PIE16/00021 & PI17/01799), Sociedad Española de Cardiología, Astra-Zeneca, Bayer, BMS and Novartis; has received consulting fees from Astra-Zeneca, Bayer, BMS-Pfizer, Novartis; and speaking fees or support for attending scientific meetings from Amgen, Astra-Zeneca, Bayer, BMS-Pfizer, Novartis, and MEDSCAPE-the heart.org. |
Vol 232
P. 164-176 - febbraio 2021 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
